Sanofi has announced a second large acquisition in the space of a month by agreeing to pay €3.9 B (US$4.8 B) for Nanobody® specialist Ablynx. Ablynx’s lead product caplacizumab is currently under review in the EU for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP). The announcement closely follows Sanofi’s acquisition of Bioverativ for US$11.6 B, a company focused on treatments for haemophilia and rare diseases.